← Asymchem Laboratories Tian Jin overview

Asymchem Laboratories Tian Jin vs Zhejiang Huahai Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Asymchem Laboratories Tian Jin Co Ltd (002821.CS)

Q3 2026
▲3▼1

Asymchem rides CRO rally, but profit drop and FX hit temper gains

  • CRO sector rally lifts Asymchem A broad CRO sector surge, sparked by WuXi AppTec's strong half-year results and raised guidance, pushed Asymchem and peers to daily limit-up. This reflects renewed demand for drug R&D outsourcing, which supports Asymchem's order book and future revenue.

    Explains the main positive force behind the stock's recent price moves.

  • AsymBio secures major investment Asymchem Group and Hillhouse Qirui are investing 1.24 billion yuan in AsymBio, a biologics CDMO subsidiary. This capital injection supports capacity expansion and growth in high-growth areas like ADCs, strengthening Asymchem's long-term competitive position.

    Shows a concrete capital commitment that boosts growth prospects.

  • First-half profit falls despite revenue growth Asymchem's first-half net profit dropped 15.7% year on year to 520 million yuan, even as revenue rose 13.1%. The decline was mainly due to currency swings; excluding FX effects, adjusted profit rose 12.9%. The headline miss may pressure the stock short-term.

    Directly addresses the earnings miss that weighs on investor sentiment.

  • Backlog surges over 50%, signaling strong demand Asymchem's total orders on hand jumped 53.8% year on year to $1.67 billion, with new orders up 54.6%. This strong backlog, especially in emerging businesses like chemical and biological macromolecule CDMO, points to robust future revenue growth and supports the stock's valuation.

    Highlights a key forward-looking indicator that offsets profit concerns.

August 2026
▲3▼1

Asymchem rides CRO rally, but profit drop and FX hit temper gains

  • CRO sector rally lifts Asymchem A broad CRO sector surge, sparked by WuXi AppTec's strong half-year results and raised guidance, pushed Asymchem and peers to daily limit-up. This reflects renewed demand for drug R&D outsourcing, which supports Asymchem's order book and future revenue.

    Explains the main positive force behind the stock's recent price moves.

  • AsymBio secures major investment Asymchem Group and Hillhouse Qirui are investing 1.24 billion yuan in AsymBio, a biologics CDMO subsidiary. This capital injection supports capacity expansion and growth in high-growth areas like ADCs, strengthening Asymchem's long-term competitive position.

    Shows a concrete capital commitment that boosts growth prospects.

  • First-half profit falls despite revenue growth Asymchem's first-half net profit dropped 15.7% year on year to 520 million yuan, even as revenue rose 13.1%. The decline was mainly due to currency swings; excluding FX effects, adjusted profit rose 12.9%. The headline miss may pressure the stock short-term.

    Directly addresses the earnings miss that weighs on investor sentiment.

  • Backlog surges over 50%, signaling strong demand Asymchem's total orders on hand jumped 53.8% year on year to $1.67 billion, with new orders up 54.6%. This strong backlog, especially in emerging businesses like chemical and biological macromolecule CDMO, points to robust future revenue growth and supports the stock's valuation.

    Highlights a key forward-looking indicator that offsets profit concerns.

Latest
▲3▼1

Asymchem rides CRO rally, but profit drop and FX hit temper gains

  • CRO sector rally lifts Asymchem A broad CRO sector surge, sparked by WuXi AppTec's strong half-year results and raised guidance, pushed Asymchem and peers to daily limit-up. This reflects renewed demand for drug R&D outsourcing, which supports Asymchem's order book and future revenue.

    Explains the main positive force behind the stock's recent price moves.

  • AsymBio secures major investment Asymchem Group and Hillhouse Qirui are investing 1.24 billion yuan in AsymBio, a biologics CDMO subsidiary. This capital injection supports capacity expansion and growth in high-growth areas like ADCs, strengthening Asymchem's long-term competitive position.

    Shows a concrete capital commitment that boosts growth prospects.

  • First-half profit falls despite revenue growth Asymchem's first-half net profit dropped 15.7% year on year to 520 million yuan, even as revenue rose 13.1%. The decline was mainly due to currency swings; excluding FX effects, adjusted profit rose 12.9%. The headline miss may pressure the stock short-term.

    Directly addresses the earnings miss that weighs on investor sentiment.

  • Backlog surges over 50%, signaling strong demand Asymchem's total orders on hand jumped 53.8% year on year to $1.67 billion, with new orders up 54.6%. This strong backlog, especially in emerging businesses like chemical and biological macromolecule CDMO, points to robust future revenue growth and supports the stock's valuation.

    Highlights a key forward-looking indicator that offsets profit concerns.

Zhejiang Huahai Pharmaceutical Co Ltd (600521.CG)

Q3 2026
▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

  • Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.

    This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.

  • Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.

    A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.

  • Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.

    Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.

  • US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.

    These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

August 2026
▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

  • Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.

    This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.

  • Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.

    A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.

  • Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.

    Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.

  • US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.

    These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

Latest
▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

  • Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.

    This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.

  • Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.

    A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.

  • Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.

    Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.

  • US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.

    These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.